JPRN-UMIN000014163已完成2 期
Phase II study of Neoadjuvant Eribulin followed by FEC for operable triple-negative breast cancer - A phase II study of Neoadjuvant Eribulin in TNBC patients
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Pregnant or breast-feeding women, or women of child bearing potential who intend to become pregnant 2) Patients with active infection 3) Patients with respiratory failure requiring oxygen inhalation therapy 4) Patients with signs or symptoms of interstitial pneumonia or pulmonary fibrosis 5) Patients who are HBs antigen-positive, HCV antibody-positive and/or HIV antibody-positive 6) Patients with diabetes mellitus associated with poor glycemic control 7) Patients with psychiatric illness that would prevent informed consent 8) Patients with history of allergy to eribulin mesylate, epirubicin hydrochloride, fluorouracil or cyclophosphamide hydrate 9) Patients with cancer within five years, not including breast cancer and lesions equivalent to carcinoma in situ or mucosal carcinoma considered healed with topical therapy 10) Patients with a history of invasive breast cancer 11) Prior treatment with Epirubicin Hydrochloride >500mg/m2 12) Patients who have a previous and concurrent inflammatory breast cancer 13) Patients otherwise considered ineligible for enrollment in the study by the investigator
研究者
相似试验
招募中
2 期
Phase II study of the combination of Eribulin and Trastuzumab Evaluating Efficacy and Safety in Patients with advanced/recurrent HER2-positive breast cancer.Advanced/recurrent HER2-positive breast cancerJPRN-UMIN000011020Sairtama Breast Cancer Clinical Study Group (SBCCSG)na35
进行中（未招募）
1 期
A Phase II study of a Combination of Eribulin and capecitabiNe in second line Treatment after the failure of gemcitabine/abraxane first line in advanced pancreatic canceradvanced pancreatic cancerMedDRA version: 21.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2017-003621-15-ITAZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA25
已完成
2 期
A phase II study of eribulin in combination with trastuzumab and pertuzumab as First-Line therapy for metastatic HER2-positive breast cancerFirst-Line therapy for metastatic HER2-positive breast cancer.JPRN-UMIN000021585Sairtama Breast Cancer Clinical Study Group (SBCCSG)16
招募中
2 期
A phase II study of neoadjuvant epirubicin/cyclophosphamide (EC) followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancerBreast cancerJPRN-UMIN000013886Tokyo Women's Medical University30
已完成
2 期
A phase II study of neoadjuvant epirubicin/cyclophosphamide (EC) followed by weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab for node-positive breast cancerbreast cancerJPRN-UMIN000007648Tokyo Women's Medical University56